wonderland

SINGAPORE, Sept 28 (Bernama-BUSINESS WIRE) — Positioned in a prime location on the highways of Selangor, Malaysia, a series of billboards highlighting “One-on-One English Courses with Foreign Teachers” attracts attention from afar. This marks the official entry of 51Talk into the Malaysian market. 51Talk is set on the path to exploring and revolutionizing the Malaysian online English education market and industry.

51Talk entered the Malaysian market in March 2020, when the world was plagued by the COVID-19 pandemic with face-to-face classes suspended as a result. Leveraging the mode of “Internet + Education,” 51Talk uses a network cable and a screen to develop a new online mode for teaching English.

51Talk selects quality teachers around the world to implement immersive one-on-one classes taught by foreign teachers. Not only can these classes effectively create an immersive English environment and enhance students’ English communication skills by enabling students to come into contact with foreign teachers at an early age, they can also encourage students to speak and communicate with others, as well as improve their English accent, pronunciation and thinking skills.

In order to help students to acquire good verbal communication skills and attain better academic results, 51Talk adopts a short, high-frequency and effective method by setting the duration of a class at 25 minutes along with pre-reading, post-class review, tests and extended reading to ensure students gain and absorb all the knowledge learnt from class for better results. On the other hand, 51Talk prides itself on having a 3% passing rate, selecting the cream of the crop for guaranteeing the quality of education.

Online learning on 51Talk enables students to utilize fragmented time to learn anytime, anywhere. Between the two years from 2020 to 2022, 51Talk has received acknowledgement and praise from numerous parents and now, as all states and federal territories in Malaysia are able to access classes provided by 51Talk, 51Talk is becoming the most reliable and effective English education brand in Malaysia.

Up to date, over 40 million 51Talk users come from 50 countries and regions, with the aggregate number of classes held amounting to over 100 million and the number of Filipino and North American teachers exceeding 20k users. Looking forward, 51Talk will continue to expand in the Malaysian market so that all Malaysian users are able to benefit from quality online English education.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20220923005421/en/

Contact

Zhang Xue
zhangxue05@51talk.com
13520550835
https://tw.51talk.com/global/course

Source : 51Talk

–BERNAMA

KUALA LUMPUR, Sept 28 (Bernama) — The need for safety management across industrial sites has increased significantly in South Korea recently, with the enforcement of the Serious Accidents Punishment Act (SAPA).

As fatal accidents on industrial sites have become a major social issue, the National Assembly has passed SAPA which took effect on Jan 27, 2022, according to a statement.

Although SAPA is not much different from the established Occupational Safety and Health Act as both Acts are aimed at preventing serious accidents while ensuring the safety of workers.

It has expanded the range of those applicable disasters to a great extent with much enhanced punishment for violating the law.

With a surge in market demand to comply with SAPA, various solutions and products have been released to take a proactive approach to prevent accidents and casualties at construction sites.

LG U+ introduced “Smart Safety Solution,” a Bluetooth and machine learning-based smart safety platform.

Meanwhile, GSIL, a smart safety company, launched a smart safety integrated platform “BE-IT” with 4th industrial technologies such as IoT, ICT, and AI, providing a solution to manage safety issues and productivity through integrated safety data in the field.

The K-ConSafety Expo, which will be held at KINTEX in Goyang from Oct 19 to 21, is a great opportunity to meet the latest products and solutions of smart construction safety companies to manage on-site safety and prevent serious accidents.

In addition to LG U+ and GSIL, POSCO ICT will participate as an official sponsor.

More details at http://www.k-consafetyexpo.com.

— BERNAMA

Tessa developing allogeneic “off-the-shelf” CD30-CAR EBVST cell therapy – TT11X – targeting relapsed or refractory CD30-positive lymphomas

SINGAPORE, Sept 15 (Bernama-GLOBE NEWSWIRE) —Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced that TT11X, the company’s allogeneic “off-the-shelf” CD30.CAR EBVST cell therapy, has been recognized in the “Most Promising Off-the-Shelf Therapies” category at the Asia-Pacific Cell & Gene Therapy Excellence Awards (ACGTEA) 2022. The ACGTEA 2022 Awards were held in conjunction with the 6^th Cell & Gene Therapy World Asia 2022.

TT11X is based on Tessa’s proprietary CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) platform. This technology was developed following decades-long research by the company’s Scientific Co-Founder, Malcolm Brenner, M.D., Ph.D., and researchers at Baylor College of Medicine, into the unique properties of virus specific T-cells (VSTs). These highly specialized T cells have the ability to recognize and kill infected cells while activating other parts of the immune system for a coordinated response. Allogeneic VSTs without any form of genetic modification have demonstrated a strong safety profile and efficacy in early trials with minimal risk of graft rejection and Graft vs Host Disease (GVHD).

Clinical data from an ongoing Phase 1 study (NCT04288726) of TT11X in CD30-positive lymphomas demonstrated a favorable safety profile and encouraging signs of efficacy with clinical responses observed in seven of nine patients, including a complete disappearance of tumors reported in four patients.

“We are very excited to be recognized among the innovators in developing ‘off-the-shelf’ cell therapy technologies and greatly appreciate the ACGTEA 2022 award,” Dr. Ivan Horak, Chief Medical Officer and Chief Scientific Officer of Tessa Therapeutics, said. “Allogeneic cell therapy technology has the potential to transform the accessibility and affordability of CAR-T, but toxicity concerns remain a key obstacle. Data from our ongoing Phase 1 trial of TT11X suggest that our CD30.CAR EBVST platform has the potential to overcome these toxicity challenges, including GVHD, while also eliciting promising signals of efficacy.”

About Tessa Therapeutics
Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors. Tessa’s lead clinical asset, TT11, is an autologous CD30-CAR-T therapy currently being investigated as a potential treatment for relapsed or refractory classical Hodgkin lymphoma as both a monotherapy (Phase 2) and combination therapy (Phase 1b). TT11 has been granted RMAT designation by the FDA and access to the PRIME scheme by European Medicine Agency. Tessa is also advancing an allogeneic “off-the- shelf” cell therapy platform targeting a broad range of cancers in which Epstein Barr Virus Specific T Cells (EBVSTs) are augmented with CD30-CAR. A therapy using this platform is currently the subject of a Phase 1 clinical trial in CD30-positive lymphomas. Tessa has its global headquarters in Singapore, where the company has built a state of the art, commercial cell therapy manufacturing facility. For more information on Tessa, visit www.tessacell.com.

Cautionary Note on Forward Looking Statements
This press release contains forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995, to the fullest extent applicable) including, without limitation, with respect to various regulatory filings or clinical study developments of the Company. You can identify these statements by the fact that they use words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, “may”, “assume” or similar expressions. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to the Company’s financial results, the ability to raise capital, dependence on strategic partnerships and licensees, the applicability of patents and proprietary technology, the timing for completion of the clinical trials of its product candidates, whether and when, if at all, the Company’s product candidates will receive marketing approval, and competition from other biopharmaceutical companies. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made, and disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. The Company’s products are expressly for investigational use pursuant to a relevant investigational device exemption granted by the U.S. Food & Drug Administration, or equivalent competent body.

Tessa Therapeutics Investor Contact

Wilson W. Cheung
Chief Financial Officer
wcheung@tessacell.com

Tessa Therapeutics Media Contact

Tiberend Strategic Advisors, Inc.
Bill Borden
+1-732-910-1620
bborden@tiberend.com

Dave Schemelia
+1-609-468-9325
dschemelia@tiberend.com

Source: Tessa Therapeutics Ltd

–BERNAMA

BEIJING, Sept. 15, 2022 /Xinhua-AsiaNet/–

The Third Video Competition on “100 Reasons To Love Beijing” was launched on September 8, 2022. Sponsored by the Information Office of Beijing Municipal People’s Government and organized by the News and Information Center, Xinhua News Agency, the contest is designed to attract Internet users from around the world to share their impression about Beijing with short videos or golden words.

Xu Hejian, director of the Information Office of the Beijing Municipal People’s Government, said in his speech the “100 Reasons To Love Beijing” Short Video Competition, a cultural outreach event initiated by the Information Office of the Beijing Municipal People’s Government, has been held successfully for two times. It attracted the participation of more than 3,000 foreign friends from over 100 countries and regions, and solicited nearly 5,000 works in the aggregate, from which many excellent videos were selected. The 2022 edition of the competition themed “How YOUNG Beijing Is” continues to solicit short videos from among foreigners who like Beijing. The competition is intended to serve as a platform for people to exchange their feelings about Beijing.

“Friendship, which derives from close contact between the people, holds the key to sound nation-to-nation relations,” Ma Jianguo, deputy director of the News and Information Center, Xinhua News Agency, said the “100 Reasons To Love Beijing ” is an activity to bring the people from all over the world to get connected, and to enable the people throughout the world to better understand Beijing. “In the run-up to the event, a lot of foreign friends sent videos to overseas branches of Xinhua News Agency, telling how and why they love Beijing”.

Beijing is an ancient capital, bearing witness to more than 3,000 years of historical vicissitudes; Beijing is also a modern city, full of vitality, and sees changes with each passing day. Since the late Ming Dynasty, Beijing has been attracting friends from all over the world. People love Beijing for different reasons. Some love Beijing’s beautiful scenery, some Beijing’s food, some the vitality of starting up businesses, and some Beijing’s cultural diversity.

The contest welcomes the entries from worldwide netizens, including the international friends who are living in Beijing, have been to Beijing, or have interest in Beijing. Anyone who is interested can email the work to lovebeijing2022 @163.com, and can talk about the topic of “100 Reasons To Love Beijing “on Weibo.

Beijing invites global netizens to come on to share the stories.

Source: Information Office of Beijing Municipal People’s Government

Image Attachments Links:

Link: http://asianetnews.net/view-attachment?attach-id=429307

Caption: The Third Video Competition on “100 Reasons To Love Beijing” was launched on September 8, 2022. 

–BERNAMA

WASHINGTON, Sept 15 (Bernama-GLOBE NEWSWIRE) — The Sabin Vaccine Institute today announced it is receiving an additional $21.8 million under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services. These funds advance development of a vaccine against Marburg virus disease, a virus that is related to Ebola Zaire which killed 2200 people during the last major outbreak that ended in 2020. The Sabin Marburg vaccine is the only candidate currently slated for a Phase 2 clinical trial. Marburg is among the world’s deadliest viruses, resulting in the death of approximately half the people the virus infects. Currently, there are no approved vaccines or treatments for the disease. As recently as July this year, two people in Ghana died after being infected with Marburg virus, reinforcing the urgent need for medical therapies. The latest tranche of funds enables Sabin to conduct a randomized, blinded, placebo-controlled clinical trial among adults in the U.S. to further evaluate the safety and the efficacy of the Marburg vaccine candidate and advance non-clinical vaccine dosing studies. The Phase 2 clinical trial in the U.S. will begin after Sabin has initiated a same-stage trial in Africa, currently scheduled for 2023. Sabin will also undertake a non-clinical study on the vaccine candidate during this phase. “Beginning Phase 2 clinical trials for the Marburg vaccine is a pivotal milestone for us and we appreciate BARDA’s continued confidence in our work and support for this critical next step,” says Sabin Chief Executive Officer Amy Finan. “Vaccines remain our best bet against death and disability from deadly viruses. I am hopeful that in the years ahead, we can offer this life-saving vaccine to every person who needs it.” In 2019, BARDA awarded Sabin a multi-year contract valued at $128 million to further the development of vaccines against two lethal viruses: Marburg and Ebola Sudan. With BARDA now exercising the latest option of that contract, Sabin’s Ebola and Marburg Research & Development program, to date, has been awarded $98.6 million. BARDA is part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50119C000555. Learn more about Sabin’s Marburg and Ebola Sudan Program. About the Sabin Vaccine Institute The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with more than two decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on Twitter, @SabinVaccine. About Ebola Sudan and Marburg Ebola Sudan and Marburg are members of the filovirus family. Both can cause severe hemorrhagic fever in humans and nonhuman primates. No therapeutic treatment of the hemorrhagic fevers caused by filoviruses has been licensed to date. Marburg and Ebola viruses are transmitted to humans by infected animals, particularly fruit bats. Once a human is infected, the virus can spread to others through close personal contact or contact with bodily fluids. Isolation of infected people is currently the centerpiece of filovirus control. Marburg was the first filovirus to be recognized in 1967 when outbreaks of hemorrhagic fever were reported in a few Europe-based laboratories including in the town of Marburg, Germany. Ebola was identified in 1976 when two simultaneous outbreaks occurred in northern Zaire (now the DRC) in a village near the Ebola River and southern Sudan. The outbreaks involved what eventually proved to be two different species of Ebola virus; both were named after the nations in which they were discovered. Media contact: Rajee Suri press@sabin.org   SOURCE : The Sabin Vaccine Institute